Thu, Jun 29, 2017
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Private Equity Strategies

Microcap Monitor: Microcap Activity on The Rise

Monday, October 21, 2013

“We’re seeing more Microcap transactional business than we’ve seen in five years,” David Bukzin, Partner at Marcum tells Private Equity Strategies, in a conversation about Microcap companies. “We’re seeing that activity across all types of transactions, IPOs, SPACs.” Bukzin works with a number of Microcap companies and private equity firms as an accountant for Marcum.

“The markets have gotten to a level where the recovery is starting to trickle down to the smaller companies. Microcap companies are the last to see the upside and the first to feel any backslide.” In our last Microcap Monitor in June, we highlighted DelMar Pharmaceuticals, a company that is working on clinical trials for an orphan disease efractory glioblastoma multiforme (GBM), the most common type of aggressive brain cancer. At that time, life sciences companies as a group were popular with investors and they still are. According to Bukzin, life sciences and technology companies continue to dominate investor interest.

“The Microcap IPO market is coming back,” he says. “These IPOs are companies with under $500 million in market value, and are in these sectors. We’re even hearing rumblings that people are exploring China again. They are looking at what companies want to go public now that a lot of them have gone dark.”

He notes that recent changes in regulation like those to Sarbanes-Oxley have improved the options for Microcap companies. The JOBS Act is also playing a limited role in terms of marketing. “Some of the companies going public now are taking advantage of the JOBS Act, but it really has had little to no effect when it comes to gaining access to capital. What has helped are the changes to Sarbanes-Oxley. Regulations overall, are a balancing act. I think SARBOX was actually helpful in many ways. But the way they’re writing some of these crowdfunding rules, they can open you up to fraud.”

SPAC’s come back

Special-purpose acquisition companies, or SPACs, are starting to become more frequent Bukzin says. Typically SPACs are a type of structure reserved for economies that are booming, but even with anemic growth, they too are coming back along with IPOs. SPAC issuances rely on IPOs to raise capital, and a few successful transactions have emboldened others to jump in.

According to research done by attorneys at Appleby, for Legal Week, “the largest such deal was the $905 million Platform Acquisitions IPO, a special purpose acquisition vehicle incorporated in the BVI and reuniting founders Martin Franklin and Nicolas Berggruen, who were previously behind the 2012 IPO of Burger King using a similar special purpose acquisition company (SPAC) model.”

Bukzin notes that the type of investor for a SPAC transaction is different from a typical IPO investor, “the IPO is more subject to market conditions, in a SPAC the equity has already been raised. With the IPO, you have to get through the SEC before you deal with the market to raise your capital. The SPAC is more institutional in nature, with an IPO you’ll see more retail investors.”

Accounting Changes

Bukzin recently gave a presentation at the JMJ Financial Summit in Las Vegas, Nevada where he highlighted some accounting changes on the horizon that could impact Microcap companies. The Public Company Accounting Oversight Board is set to have a public roundtable next year that could change the auditors’ opinion from pass/fail to something more qualitative. The proposal would add more communication to the auditors report about issues that came up during the audit leading to the opinion.

The Financial Accounting Standards Board (FASB) is also considering some regulatory relief on reporting for development stage companies. Those changes would affect mostly pharmaceutical, biotechnology, and technology companies. Based upon current rules it is difficult for companies to emerge from development stage to an established operating company because current guidance requires meeting the same reporting guidelines as an established operation. The FASB is looking at ways to make these reporting requirements easier for development stage companies.

These rules and a more liquid market environment are bolstering Microcap activity. “We’re seeing clients who are now able to get capital in the last six months, where they haven’t been able to for the past five years,” Bukzin says. “There’s an arbitrage in Microcap because of the lack of liquidity, which creates a lower valuation and private equity firms can take advantage of that.”

Research submitted by Perritt Capital Management following this article goes into those issues in detail. Watch this space.

 
This article was published in Opalesque's Private Equity Strategies our monthly research update on the global private equity landscape including all sectors and market caps.
Private Equity Strategies
Private Equity Strategies
Private Equity Strategies
Private Equity Strategies


Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. FinTech - AI hedge fund Numerai now live on Ethereum, Cryptocurrency hedge funds generate huge returns as bitcoin surges[more]

    AI hedge fund Numerai now live on Ethereum From Cryptoninjas.net: Back in February, Numerai announced numeraire (NMR), a cryptographic token to incentivize a new kind of hedge fund built by a network of data scientists. Earlier today, the Numeraire smart contract was officially deployed

  2. Investing - Advisors slash hedge fund positions, Theravance Biopharma is a top pick of investment guru Seth Klarman, As asset management industry grows a search for new revenue streams[more]

    Advisors slash hedge fund positions From Barrons.com: Financial advisors have cut wealthy clients' exposure to hedge funds by up to one third over the past 12 months, The Financial Times reports. Advisor firms in the FT's annual top-300 ranking have reduced their hedge fund allocation to

  3. Investing - U.S. hedge fund in anonymous bet against Tesco shares, Hedge funds made repeated attempts to invest in Veneto banks, Steve Cohen's Point72 takes stake in struggling electronics retailer Conn's, Hedge fund Excalibur bets Riksbank will tighten by end of year[more]

    U.S. hedge fund in anonymous bet against Tesco shares From FT.com: A $20bn New York hedge fund is using an offshore shell company to anonymously bet against the shares of the UK supermarket Tesco, raising fresh questions over the efficacy of European short selling disclosure rules.

  4. Investing - In Amazon's shadow, hedge funds take aim at Brexit-hit retailers[more]

    From NYTimes.com: Hedge funds have significantly stepped up bets against Britain's traditional high street retailers, as the sector struggles with online competition, worries about a stretched consumer and weakening sales and profits. The risks were on full display on Tuesday when shares in Debenham

  5. Barclay Hedge Fund index gains 0.50% in May, 4.13% YTD[more]

    Hedge funds gained 0.50% in May according to the Barclay Hedge Fund Index compiled by BarclayHedge. The Index is up 4.13% in 2017. The Barclay Hedge Fund Index has now been profitable for seven months in a row, with a cumulative gain of 6.10%. The Barclay Technology Index has gained 12.27% in the fi